by April Breyer Menon | Sep 12, 2023
Download PDF Download...
by April Breyer Menon | Aug 15, 2023
Download PDF Download...
by April Breyer Menon | Aug 14, 2023
The Act’s Objectives USPTO data indicate that as many as 80% of instituted Patent Trial and Appeal Board (PTAB) proceedings that reach a final written decision (FWD) result in the invalidation of at least one challenged patent claim, with 65% of those proceedings...
by April Breyer Menon | Aug 7, 2023
At the beginning of July, seven additional Humira® (adalimumab) biosimilars, including one interchangeable, joined Amjevita™ (adalimumab-atto) in the US marketplace. Abrilada™ (adalimumab-afzb) is the only FDA-approved adalimumab biosimilar that has not...
by April Breyer Menon | Jul 31, 2023
As of July 24, 2023, the United States Patent and Trademark Office (USPTO) revised the interim Director Review process and replaced the Precedential Opinion Panel (POP) with the Appeals Review Panel process, which will review decisions in ex parte, re-examination, and...